Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 252 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: daratumumab Clear all
Active, not recruiting Phase 2 Interventional

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

NCT05231629
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT04956302
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Panobinostat Lactate
Drug
Lead sponsor
Abdullah Khan
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT06974786
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

NCT03187262
View directory record Official record
Conditions
Waldenström Macroglobulinemia
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 25, 2026, 9:23 PM EDT
Not listed Phase 2 Interventional

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT03942224
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Ixazomib
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions
Linvoseltamab, Daratumumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT03012880
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Daratumumab, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

NCT03481556
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib, Daratumumab
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

NCT01749969
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, lenalidomide, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D, Ramantamig
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional Results available

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Modakafusp alfa, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia
Interventions
Daratumumab / Hyaluronidase Injection
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

NCT02488759
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, Daratumumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 25, 2026, 9:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04776018
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

NCT03275285
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, carfilzomib, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
San Francisco, California • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT03439293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Daratumumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Anaheim, California • Denver, Colorado • Tallahassee, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 25, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804
View directory record Official record
Conditions
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Interventions
Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Multigated Acquisition Scan, Biospecimen Collection, Echocardiography, Chest Radiography
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 9:23 PM EDT
Recruiting Phase 3 Interventional

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
45
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 9:23 PM EDT